Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acceptability of Darunavir/Cobicistat FDC in HIV-1 Infected Children
NCT05197075Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of darunavir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of Participants with Ability to Take the Darunavir/Cobicistat (DRV/COBI) Fixed Dosed Combination (FDC) Tablet Dispersed in Water as Reported by the Observer at Day 1. Started Aug 2022; status: completed.
02
Drugs
darunavir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05197075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05197075.